 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 GLOBE NEWSWIRE -- Sio Gene Therapies Inc. NASDAQ: SIOX, a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that the first patient has been dosed in the high-dose cohort of the Phase 12 Stage 1 study for Type I infantile and Type II late infantile and juvenile onset GM1 gangliosidosis. 